<DOC>
	<DOCNO>NCT00249795</DOCNO>
	<brief_summary>The purpose study determine Irbesartan compare Placebo would reduce risk vascular event heart attack , stroke , non-cerebral thromboembolic event death patient Atrial Fibrillation ( AF ) least one major risk vascular event .</brief_summary>
	<brief_title>Atrial Fibrillation Clopidogrel Trial With Irbesartan Prevention Vascular Events ( ACTIVE I )</brief_title>
	<detailed_description>ACTIVE I one 3 separate relate trial ACTIVE program conduct AF patient risk vascular event . Patients enrol first one 2 parallel trial ACTIVE program evaluating Clopidogrel : - ACTIVE A comparing clopidogrel + acetylsalicylic acid ( ASA ) ASA alone - ACTIVE W compare clopidogrel + ASA oral anticoagulant ( OAC ) . Then satisfy additional criterion relate blood pressure angiotensin receptor block agent re-randomized two ACTIVE I arm accord separate randomization list .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<criteria>Should fulfill eligibility criterion ACTIVE A ACTIVE W trial : systolic blood pressure least 110 mmHg already receive angiotensin receptor block agent , unless willing able change another antihypertensive agent previous intolerance angiotensin receptor block agent proven indication angiotensin receptor block agent , unless Angiotensin Converting Enzyme ( ACE ) inhibitor substitute Patients exclude ACTIVE study follow present : requirement clopidogrel ( recent coronary stent procedure ) requirement oral anticoagulant ( prosthetic mechanical heart valve ) prior intolerance acetylsalicyclic acid ( ASA ) clopidogrel document peptic ulcer disease within previous 6 month prior intracerebral hemorrhage significant thrombocytopenia ( platelet count &lt; 50 x 10 ( 9 ) /L ) psychosocial reason make study participation impractical geographic reason make study participation impractical ongoing alcohol abuse mitral stenosis pregnant nursing woman woman child bear potential effective birth control least one month prior start study willing continue birth control duration study severe comorbid condition patient expect survive 6 month patient currently receive investigational pharmacologic agent requirement chronic ( &gt; 3 month ) noncyclooxygenase2 ( nonCOX2 ) inhibitor nonsteroidal antiinflammatory drug ( NSAID ) therapy unless willing enrol ACTIVE A</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Atrial fibrillation</keyword>
	<keyword>Cardiovascular disease</keyword>
	<keyword>angiotensin II blocker</keyword>
</DOC>